BRPI1008039A2 - composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica - Google Patents

composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica

Info

Publication number
BRPI1008039A2
BRPI1008039A2 BRPI1008039A BRPI1008039A BRPI1008039A2 BR PI1008039 A2 BRPI1008039 A2 BR PI1008039A2 BR PI1008039 A BRPI1008039 A BR PI1008039A BR PI1008039 A BRPI1008039 A BR PI1008039A BR PI1008039 A2 BRPI1008039 A2 BR PI1008039A2
Authority
BR
Brazil
Prior art keywords
compound
mixture
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI1008039A
Other languages
English (en)
Inventor
Daniel B De Oliveira
Kevin L Zhou
Zheng Xin Dong
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of BRPI1008039A2 publication Critical patent/BRPI1008039A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI1008039A 2009-02-20 2010-02-19 composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica BRPI1008039A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20815409P 2009-02-20 2009-02-20
PCT/US2010/000473 WO2010096175A1 (en) 2009-02-20 2010-02-19 Cytotoxic conjugates having neuropeptide y receptor binding compound

Publications (1)

Publication Number Publication Date
BRPI1008039A2 true BRPI1008039A2 (pt) 2016-10-04

Family

ID=42634162

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008039A BRPI1008039A2 (pt) 2009-02-20 2010-02-19 composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica

Country Status (12)

Country Link
US (1) US8877715B2 (pt)
EP (1) EP2398492A4 (pt)
JP (1) JP5584236B2 (pt)
KR (1) KR101413051B1 (pt)
CN (1) CN102325545A (pt)
AU (1) AU2010216372B2 (pt)
BR (1) BRPI1008039A2 (pt)
CA (1) CA2752608A1 (pt)
EA (1) EA020613B1 (pt)
MX (1) MX2011008774A (pt)
UA (1) UA102432C2 (pt)
WO (1) WO2010096175A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
EP2708243A1 (en) * 2012-09-17 2014-03-19 OntoChem GmbH Receptor ligand linked cytotoxic molecules
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
HK1213486A1 (zh) 2012-11-01 2016-07-08 Ipsen Pharma S.A.S. 促生长素抑制素类似物及其二聚体
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
US10246497B2 (en) 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
CA2988500A1 (en) 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof
US10064855B2 (en) 2016-03-08 2018-09-04 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
WO2017156183A1 (en) * 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
CN106279287B (zh) * 2016-08-12 2018-11-30 华中科技大学 一种喜树碱磷酸酯类化合物、其制备方法及应用
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
ES2928207T5 (en) * 2018-04-10 2026-02-16 Sanofi Aventis Deutschland Lixisenatide synthesis with capping
WO2021013999A1 (en) * 2019-07-24 2021-01-28 Ontochem Gmbh Receptor-targeting peptide-drug conjugates
CN118240015B (zh) * 2024-03-21 2025-03-21 中国科学院近代物理研究所 一种针对脑胶质瘤的靶向多肽及放射性示踪剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11501281A (ja) * 1993-06-18 1999-02-02 ユニバーシティ オブ シンシナティ 神経ペプチドｙアンタゴニスト及びアゴニスト
US20030022277A1 (en) * 1995-05-05 2003-01-30 Daniel R. Soppet Human neuropeptide receptor
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
EP1208852B1 (en) * 2000-11-24 2007-08-01 Jean-Claude Reubi Neuropeptide Y1 receptor binding compounds in the treatment and diagnosis of cancer
WO2007039318A2 (en) * 2005-10-06 2007-04-12 Bayer Schering Pharma Aktiengesellschaft Neuropeptide y analogs
EP1900742A1 (en) * 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
EP2084178B1 (en) * 2006-10-20 2011-12-07 Ipsen Pharma S.A.S. Peptide-cytotoxic conjugates
EP2604283A1 (en) * 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
AU2010216383B2 (en) * 2009-02-20 2013-06-20 Ipsen Pharma S.A.S. Analogues of neuropeptide Y having at least one synthetic amino acid substitution

Also Published As

Publication number Publication date
EA020613B1 (ru) 2014-12-30
EP2398492A1 (en) 2011-12-28
EA201171074A1 (ru) 2012-04-30
WO2010096175A1 (en) 2010-08-26
US20120010154A1 (en) 2012-01-12
KR101413051B1 (ko) 2014-07-31
JP5584236B2 (ja) 2014-09-03
JP2012518636A (ja) 2012-08-16
MX2011008774A (es) 2011-10-24
US8877715B2 (en) 2014-11-04
CN102325545A (zh) 2012-01-18
AU2010216372B2 (en) 2013-06-20
KR20110125235A (ko) 2011-11-18
CA2752608A1 (en) 2010-08-26
AU2010216372A1 (en) 2011-09-15
UA102432C2 (ru) 2013-07-10
EP2398492A4 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0913410A2 (pt) uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica
BRPI1014316A2 (pt) composição, e, uso de uma composição
BRPI1005931A2 (pt) associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 7A ANUIDADES. PAGAR RESTAURACAO.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]